GlassScriptPhysician profile
Branden Shaffer
NPI 1568014330
$9,444.93
in general payments reported to CMS, 2019-2025
27 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $58.75 · 2021: $2,917 · 2022: $1,543 · 2023: $1,846 · 2024: $1,607 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $1,861.11 | 2020-2021 | |
| Glaukos Corporation | $1,600.31 | 2022-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose, Istent Infinite |
| Abbvie INC. | $945.38 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $691.17 | 2020-2022 | |
| Alcon Vision LLC | $691.11 | 2022-2025 | Wavelight Refractive Suite, Rocklatan, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $544.16 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Rxsight INC | $357.15 | 2020-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Dompe US, INC. | $312.35 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $256.84 | 2019-2021 | |
| Thea Pharma INC. | $253.31 | 2023-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $239.36 | 2021-2023 | |
| Tarsus Pharmaceuticals, INC. | $203.33 | 2025 | Xdemvy |
| Harrow Eye, LLC | $183.88 | 2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $137.33 | 2024 | Syfovre |
| Johnson & Johnson Vision Care, INC. | $127.36 | 2023 | Acuvue |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $123.85 | 2022 | |
| Mallinckrodt Hospital Products INC. | $123.42 | 2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.27 | 2019-2021 | |
| Astellas Pharma US INC | $121.18 | 2023 | |
| Sight Sciences, INC. | $104.54 | 2021-2024 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $97.69 | 2021 | |
| New World Medical,INC. | $96.18 | 2022-2023 | |
| Ivantis, INC | $86.15 | 2021 | |
| Oyster Point Pharma, INC. | $70.54 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Coopervision INC. | $60.60 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $18.65 | 2022 | |
| Lkc Technologies, INC. | $14.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Branden Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.